These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20812145)

  • 1. Modulation of the vasopressin system for the treatment of CNS diseases.
    Ryckmans T
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin V1a and V1b receptors: from molecules to physiological systems.
    Koshimizu TA; Nakamura K; Egashira N; Hiroyama M; Nonoguchi H; Tanoue A
    Physiol Rev; 2012 Oct; 92(4):1813-64. PubMed ID: 23073632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the discovery and development of negative allosteric modulators of mGluR5.
    Lindsley CW; Emmitte KA
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):446-57. PubMed ID: 19562641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system effects of the neurohypophyseal hormones and related peptides.
    de Wied D; Diamant M; Fodor M
    Front Neuroendocrinol; 1993 Oct; 14(4):251-302. PubMed ID: 8258377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin receptor antagonists: potential indications and clinical results.
    Arai Y; Fujimori A; Sudoh K; Sasamata M
    Curr Opin Pharmacol; 2007 Apr; 7(2):124-9. PubMed ID: 17292670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
    Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
    Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.
    Serradeil-Le Gal C; Derick S; Brossard G; Manning M; Simiand J; Gaillard R; Griebel G; Guillon G
    Stress; 2003 Sep; 6(3):199-206. PubMed ID: 13129813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders.
    Szczepanska-Sadowska E; Zera T; Sosnowski P; Cudnoch-Jedrzejewska A; Puszko A; Misicka A
    Curr Drug Metab; 2017; 18(4):306-345. PubMed ID: 28117000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene.
    Mayinger B; Hensen J
    Exp Clin Endocrinol Diabetes; 1999; 107(3):157-65. PubMed ID: 10376439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central vasopressin and oxytocin release: regulation of complex social behaviours.
    Veenema AH; Neumann ID
    Prog Brain Res; 2008; 170():261-76. PubMed ID: 18655888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a single administration of oxytocin or vasopressin and their interactions with two selective receptor antagonists on memory storage in mice.
    Boccia MM; Kopf SR; Baratti CM
    Neurobiol Learn Mem; 1998 Mar; 69(2):136-46. PubMed ID: 9619993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.
    Folny V; Raufaste D; Lukovic L; Pouzet B; Rochard P; Pascal M; Serradeil-Le Gal C
    Am J Physiol Endocrinol Metab; 2003 Sep; 285(3):E566-76. PubMed ID: 12736162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.